Literature DB >> 19180473

Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.

S Alice Long1, Mindi R Walker, Mary Rieck, Eddie James, William W Kwok, Srinath Sanda, Catherine Pihoker, Carla Greenbaum, Gerald T Nepom, Jane H Buckner.   

Abstract

CD4(+)CD25(+)FOXP3(+) Treg cells require TCR engagement for suppressive function, thus ensuring that suppression occurs only in the presence of specific antigens; however, to date no studies have addressed the function of self-antigen-specific Treg in humans. These studies were designed to determine whether peripheral generation and function of islet antigen-specific adaptive Treg are defective in human subjects with type 1 diabetes (T1D). Islet antigen-specific adaptive Treg were induced in vitro by activation of CD4(+)FOXP3(-) T cells with glutamic acid decarboxylase and islet-specific glucose-6-phosphate catalytic subunit-related protein peptides in the context of T1D-associated HLA-DRbeta alleles. Antigen-specific Treg were characterized using flow cytometry for FOXP3 and class II tetramer and assessed for the ability to inhibit proliferation. These adaptive Treg were then compared with influenza-specific Treg from the same study population. The function of tetramer(+) cells that expressed FOXP3 was similar for both influenza and islet antigens generated from control and T1D subjects. In fact, the potency of suppression correlated with FOXP3 expression, not antigen specificity. Thus, these data suggest that development of functional adaptive Treg can occur in response to islet antigens and activation of islet-specific Treg may potentially be used as a targeted immunotherapy in T1D.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19180473      PMCID: PMC2743096          DOI: 10.1002/eji.200838819

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  43 in total

1.  Multiplex mapping of CD4 T cell epitopes using class II tetramers.

Authors:  Junbao Yang; Eddie A James; Laurie Huston; Nancy A Danke; Andrew W Liu; William W Kwok
Journal:  Clin Immunol       Date:  2006-05-04       Impact factor: 3.969

2.  Regulatory T cell development in the absence of functional Foxp3.

Authors:  Wen Lin; Dipica Haribhai; Lance M Relland; Nga Truong; Marc R Carlson; Calvin B Williams; Talal A Chatila
Journal:  Nat Immunol       Date:  2007-02-02       Impact factor: 25.606

3.  Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3.

Authors:  Sarah E Allan; Alicia N Alstad; Natacha Merindol; Natasha K Crellin; Mario Amendola; Rosa Bacchetta; Luigi Naldini; Maria Grazia Roncarolo; Hugo Soudeyns; Megan K Levings
Journal:  Mol Ther       Date:  2007-11-06       Impact factor: 11.454

4.  Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells.

Authors:  Rafal Pacholczyk; Joanna Kern; Nagendra Singh; Makio Iwashima; Piotr Kraj; Leszek Ignatowicz
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

5.  Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo.

Authors:  Milica Vukmanovic-Stejic; Yan Zhang; Joanne E Cook; Jean M Fletcher; Arthur McQuaid; Joanne E Masters; Malcolm H A Rustin; Leonie S Taams; Peter C L Beverley; Derek C Macallan; Arne N Akbar
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

6.  No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes.

Authors:  Todd Brusko; Clive Wasserfall; Kieran McGrail; Richard Schatz; Hilla Lee Viener; Desmond Schatz; Michael Haller; Jennifer Rockell; Peter Gottlieb; Michael Clare-Salzler; Mark Atkinson
Journal:  Diabetes       Date:  2007-03       Impact factor: 9.461

7.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.

Authors:  Jun Wang; Andreea Ioan-Facsinay; Ellen I H van der Voort; Tom W J Huizinga; René E M Toes
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

8.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.

Authors:  Sarah E Allan; Sarah Q Crome; Natasha K Crellin; Laura Passerini; Theodore S Steiner; Rosa Bacchetta; Maria G Roncarolo; Megan K Levings
Journal:  Int Immunol       Date:  2007-02-27       Impact factor: 4.823

9.  Defective regulatory and effector T cell functions in patients with FOXP3 mutations.

Authors:  Rosa Bacchetta; Laura Passerini; Eleonora Gambineri; Minyue Dai; Sarah E Allan; Lucia Perroni; Franca Dagna-Bricarelli; Claudia Sartirana; Susanne Matthes-Martin; Anita Lawitschka; Chiara Azzari; Steven F Ziegler; Megan K Levings; Maria Grazia Roncarolo
Journal:  J Clin Invest       Date:  2006-06       Impact factor: 14.808

10.  Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice.

Authors:  Kristin V Tarbell; Lucine Petit; Xiaopan Zuo; Priscilla Toy; Xunrong Luo; Amina Mqadmi; Hua Yang; Manikkam Suthanthiran; Svetlana Mojsov; Ralph M Steinman
Journal:  J Exp Med       Date:  2007-01-08       Impact factor: 14.307

View more
  18 in total

Review 1.  MHC class II tetramers.

Authors:  Gerald T Nepom
Journal:  J Immunol       Date:  2012-03-15       Impact factor: 5.422

Review 2.  Challenges in the pursuit of immune tolerance.

Authors:  Gerald T Nepom; E William St Clair; Laurence A Turka
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 3.  Harnessing memory adaptive regulatory T cells to control autoimmunity in type 1 diabetes.

Authors:  Cheng-Rui Li; Bas J G Baaten; Linda M Bradley
Journal:  J Mol Cell Biol       Date:  2011-11-24       Impact factor: 6.216

4.  Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells.

Authors:  S Alice Long; Mary Rieck; Megan Tatum; Paul L Bollyky; Rebecca P Wu; Isabelle Muller; Jhon-Chun Ho; Heather G Shilling; Jane H Buckner
Journal:  J Immunol       Date:  2011-08-24       Impact factor: 5.422

5.  IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-β7-dependent localization.

Authors:  Cheng-Rui Li; Mia F Deiro; Elana Godebu; Linda M Bradley
Journal:  J Autoimmun       Date:  2011-07-13       Impact factor: 7.094

6.  Identification of HIV-1-specific regulatory T-cells using HLA class II tetramers.

Authors:  Mathieu Angin; Melanie King; Marcus Altfeld; Bruce D Walker; Kai W Wucherpfennig; Marylyn M Addo
Journal:  AIDS       Date:  2012-10-23       Impact factor: 4.177

Review 7.  CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game.

Authors:  S Alice Long; Jane H Buckner
Journal:  J Immunol       Date:  2011-09-01       Impact factor: 5.422

8.  Targeting CD44 augments the efficacy of Tregs in autoimmune diabetes.

Authors:  Cheng-Rui Li; Erin E Mueller; Linda M Bradley
Journal:  Immunol Lett       Date:  2014-10-22       Impact factor: 3.685

9.  Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.

Authors:  Jianfei Qian; Sungyoul Hong; Siqing Wang; Liang Zhang; Luhong Sun; Michael Wang; Jing Yang; Larry W Kwak; Jian Hou; Qing Yi
Journal:  Blood       Date:  2009-08-04       Impact factor: 22.113

10.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.